BioSpace News Archive

Can more personalized cancer care lead to better outcomes and improved patient satisfaction among cancer patients? Cindi Slater , MD, FACR, senior vice president of Medical Affairs for national expert medical guidance company ConsumerMedical, will give a presentation addressing that topic at the Pittsburgh Business Group on Health (PBG

Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B SOMERVILLE, Mass.--( BUSINESS WIRE )-- Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today a $90 million Series D financing. New investors in the roun

Aravive, Inc., a clinical-stage biopharmaceutical company developing transformative therapeutics, announced that Michael W. Rogers joined the Company’s Board of Directors.

Patients who received Opdivo plus Yervoy maintained durable responses, with the combination showing improved duration of response vs. sunitinib

Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces it has applied to the TSX to extend the term of an aggregate of 7,413,052 common share purchase warrants which were issued in connection with Microbix’s October, 2015 and October, 2017 private placement financings.

Passage Bio, Inc. announced publication of data supporting development of its gene therapy PBFTO2 for patients with frontotemporal dementia caused by mutations in the granulin gene.

Dogma Therapeutics has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commercial milestones.

Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang , will pre

Medical and Dental well positioned as elective procedures positively rebound - COVID fourth quarter impact on elective procedures less severe than expected - Elective procedures rebounded to approximately 80% - 85% of pre-COVID levels and strengthening - Net sales of $233.4M, down 2.5% - GAAP diluted EPS of $(0.05), down 125.5% - Non-GAAP diluted EPS of $0.24, down 62.6% - GAAP net loss of $(2.3)M, down 125.6% - Non-GAAP net i

Dr. Reddy’s Laboratories Ltd. announced the launch of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration.